Abstract：Objective To evaluate the treatment outcomes in lung cancer patients with brain metastases (BM) after stereotactic radiotherapy (SRT) according to magnetic resonance imaging (MRI) findings and the Response Evaluation Criteria In Solid Tumors (RECIST). Methods A retrospective analysis was performed on 31 lung cancer patients with 60 BM lesions who were treated with SRT. Tumor responses were evaluated according to MRI findings and the RECIST. Results The MRI after SRT showed that (1) 14 lesions recurred, with nodular enhancement in 8 lesions, homogeneous enhancement in 5 lesions, and inhomogeneous enhancement in 1 lesion;(2) 11 lesions (18%) had suspected progression, with homogeneous enhancement in 5 lesions, inhomogeneous enhancement in 3 lesions, peripheral enhancement in 2 lesions, and nodular enhancement in 1 lesion;(3) 35 lesions were controlled, with decreased volume or disappearance in 19 lesions, insignificant volume change in 10 lesions, and increased volume in 6 lesions;(4) the overall response rate was 76.7%(suspected progression+ controlled). According to the RECIST, 15 lesions (25%) achieved a complete response (CR), 9 lesions (15%) achieved a partial response (PR), 12 lesions (20%) had stable disease, and 24 lesions (40%) had progressive disease, and the response rate (CR+PR) was 40%. Conclusions There are various MRI findings for brain metastases in lung cancer patients after SRT, and 18% of the lesions are difficult to evaluate by MRI. RECIST underestimates the short-term effect of SRT.
Li Xiangpan,Xiao Jianping,Chen Xiujun et al. Evaluation of MRI findings and short-term outcome in lung cancer patients with brain metastases after stereotactic radiotherapy[J]. Chinese Journal of Radiation Oncology, 2014, 23(1): 40-42.
[1] Huber PE, Hawighorst H, Fuss M, et al. Transient enlargement of contrast uptake on MRI after linear accelerator (linac) stereotactic radiosurgery for brain metastases[J]. Int J Radiat Oncol Biol Phys,2001,49:1339-1349. [2] Khuntia D, Brown P, Li J, et al. Whole-brain radiotherapy in the management of brain metastasis[J]. J Clin Oncol,2006,24:1295-1304. [3] Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors[J]. J Nat Cancer Ins,2000,92:205-216. [4] Simpson JR, Mendenhall WM, Schupak KD, et al. Follow-up and retreatment of brain metastasis. American college of radiology. ACR appropriateness criteria[J]. Radiology,2000,215 Suppl:1129-1135. [5] Chernov MF, Ono Y, Abe K, et al. Differentiation of tumor progression and radiation-induced effects after intracranial radiosurgery[A]//Hayashi M, Ganz JC, Takakura K,et al. Gamma knife neurosurgery in the management of intracranial disorders[M]. New York:Springer,2013:193-210. [6] Bindal AK, Bindal RK, Hess KR, et al. Surgery versus radiosurgery in the treatment of brain metastasis[J]. J Neurosurg,1996,84:748-754. [7] Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation:a randomised controlled trial[J]. Lancet Oncol,2009,10:1037-1044. [8] Rogers L, Gutierrez J, Scarpace L, et al. Morphologic magnetic resonance imaging features of therapy-induced cerebral necrosis[J]. J Neurooncol,2011,101:25-32. [9] Soussain C, Ricard D, Fike JR, et al. CNS complications of radiotherapy and chemotherapy[J]. Lancet,2009,374:1639-1651. [10] Ross DA, Sandler HM, Balter JM, et al. Imaging changes after stereotactic radiosurgery of primary and secondary malignant brain tumors[J]. J Neurooncol,2002,56:175-181. [11] Peterson AM, Meltzer CC, Evanson EJ, et al. MR imaging response of brain metastases after gamma knife stereotactic radiosurgery[J]. Radiology,1999,211:807-814. [12] Kocher M, Soffietti R, Abacioglu U, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases:results of the EORTC 22952－26001 study[J]. J Clin Oncol,2011,29:134-141. [13] Marko NF, Angelov L, Toms SA, et al. Stereotactic radiosurgery as single-modality treatment of incidentally identified renal cell carcinoma brain metastases[J]. World Neurosurg,2010,73:186-193.
2014, Vol. 23 
